Amphotericin B colloidal dispersion

Bibliography

• SOKOL-ANDERSON ML, BRAJTBURG J, MEDOFF G:Amphotericin-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. (1986) 154:76–83.
   PubMed Web of Science ®Google Scholar
• BRAJTBURG J, POWDERLY WG, KOBAYASHI GS,MEDOFF G: Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. (1990) 34:183–188.
   PubMed Web of Science ®Google Scholar
• CHIA JKS, MCMANUS EJ: In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associ-ated with amphotericin B preparations. Antimicrob. Agents Chemother. (1990) 34:906–908.
   PubMed Web of Science ®Google Scholar
• GIGLIOTTI F, SHENEP JL, LOTT L, THORNTON D: Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis. (1987) 156(5)784–789.
   Google Scholar
• GELFAND JA, KIMBALL K, BURKE JF et al.: Amphotericin B treatment of human mononuclear cells results in secretion of tumor necrosis factor and IL-1. Clin. Res. (1988) 36:456A.
   Google Scholar
• ARNING M, KLICHE KO, HEERSONDERHOFF AH, WEHMEIER A: Infusion-related toxicity of three different amphotericin B formulations and its relation tocytokine plasma levels. Mycoses (1 9 9 5)38(11–12):459–465.
   Google Scholar
• LE Y, RANA KZ, DUDLEY MN: Amphotericin B-associated hypertension. Ann. Pharmacother. (1996) 30(7–8)765–767.
   Google Scholar
• BARLOWS TGR, LUBER AD, JACOBS RA, GUGLIELMO BJ: Hypothermia following the intravenous administra-tion of amphotericin B. Clin. Infect. Dis. (1996) 23(5):1187–1188.
   PubMed Web of Science ®Google Scholar
• LEVY M, DOMARATZKI J, KOREN G: Amphotericin-induced heart-rate decrease in children. Clin. PediaL (1995) 34(7):358–364.
   PubMed Web of Science ®Google Scholar
• SAWAYA BP, BRIGGS JP, SCHNERMANN J: Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. (1995) 6(2):154–164.
   PubMed Web of Science ®Google Scholar
• SABRA R, BRANCH RA: Amphotericin B nephrotoxicity. Drug Safety (1990) 5(2):94–108.
   PubMed Web of Science ®Google Scholar
• BUTLER WT, BENNETT JE, ALLING DW, WERTLAKE PT, UTZ JP, HILL GJI: Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann. Intern. Med. (1964) 61:175–187.
   PubMed Web of Science ®Google Scholar
• BURGESS JL, BIRCHALL R: Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am. J. Med. (1972) 53(1):77–84.
   PubMed Web of Science ®Google Scholar
• CHENG JT, WITTY RT, ROBINSON RR, YARGER WE: Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Intern. (1982) 22(6)626–633.
   Google Scholar
• KOLDIN MH, KOBAYASHI GS, BRAJTBURG J, MEDOFF G:Effects of elevation of serum cholesterol and admini-stration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimi-crob. Agents Chemother. (1985) 28(1):144–145.
   PubMed Web of Science ®Google Scholar
• WASAN KM, LOPEZ-BERESTEIN G: The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J. Drug Target. (1994) 2 (5) 373–380.
   PubMed Web of Science ®Google Scholar
• WASAN KM, KENNEDY AL, CASSIDY SM et al.: Pharma-cokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholestero-lemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. (1998) 42(12):3146–3152.
   PubMed Web of Science ®Google Scholar
• WASAN KM, CONKLIN JS: Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. (1997) 24(1):78–80.
   PubMed Web of Science ®Google Scholar
• LIN AC, GOLDWASSER E, BERNARD EM, CHAPMAN SW: Amphotericin B blunts erythropoietin response to anemia. J. Infect. Dis. (1990) 161(2):348–351.
   PubMed Web of Science ®Google Scholar
• MACGREGOR RR, BENNETT JE, ERSLEV AJ: Erythro-poietin concentration in amphotericin B-induced anemia. Antimicrob. Agents Chemother. (1 9 7 8) 14 (2):270–273.
   Google Scholar
• WALSH TJ, LYMAN CA: New antiftmgal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Cancer Treat. Res. (1995) 79:113–148.
   PubMedGoogle Scholar
• LI PK, LAI KN: Amphotericin B induced ocular toxicity in cryptococcal meningitis. Br. J. Ophthalmol. (1989) 73 (5):397–398.
   PubMed Web of Science ®Google Scholar
• DEVUYST 0, GOFFIN E, VAN YPERSELE DE STRIHOU C: Recurrent hemiparesis under amphotericin B for Candida albicans peritonitis. Nephrol., Dialysis, Transplant. (1995) 1O(5):699–701.
   Google Scholar
• LIU JS, CHANG YY, CHEN WH, CHEN SS: Amphotericin B-induced leukoencephalopathy in a patient with cryptococcal meningitis. J. Formosan Med. Assoc. (1995) 94 (7):432–434.
   PubMed Web of Science ®Google Scholar
• HARTSEL S, BOLARD J: Amphotericin B: new life for an old drug. Trends Pharm. ScL (1996) 17(12):445–449.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl. J. Med. (1999) 340(10) 764–771
   Google Scholar
• WHITE MH, BOWDEN RA, SANDLER ES et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Infect. Dis. (1998) 27(2):296–302.
   Google Scholar
• ••Randomised, double-blind clinical trial of ABCD versusamphotericin B deoxycholate in the empirical treatment of febrile neutropenia.
   Google Scholar
• GRAYBILL JP: Lipid formulations for amphotericin B: does the emperor need new clothes? Ann. Int. Med. (1996) 124(10921–923.
   Google Scholar
• ORAVCOVA E, MISTRIK M, SAKALOVA A et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy (1995) 41(6)473–476.
   Google Scholar
• SPEELEVELD E, GORDTS B, VANLANDUYT HW, DEVROEY C, RAESWUYTACK C: Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses (1996) 39(1–2)37–40.
   Google Scholar
• WARNOCK DW: Amphotericin B: an introduction. J. Antimicro. Chemother. (1991) 28:27–38.
   PubMed Web of Science ®Google Scholar
• CROSS JT, JR., HICKERSON SL, YAMAUCHI T: Antiftmgal drugs. Pedial Rev. (1995) 16(4):123–129.
   PubMedGoogle Scholar
• STERLING TR, GASSER RA, JR., ZIEGLER A: Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. (1996) 23(0:187–188.
   Google Scholar
• GEORGOPAPADAKOU NH, WALSH TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. (1996) 40:279–291.
   PubMed Web of Science ®Google Scholar
• JOHNSON EM, OJWANG JO, SZEKELY A, WALLACE TL,WARNOCK DW: Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. (1998) 42(6):1412–1416.
   PubMed Web of Science ®Google Scholar
• HANSON LH, STEVENS DA: Comparison of antifungalactivity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. (1992) 36(2):486–488.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. (1991) 35(9):1829–1833.
   PubMed Web of Science ®Google Scholar
• •Study of the comparative activity of ABCD and amphotericin B deoxycholate in treatment of experimental coccidioidomycosis.
   Google Scholar
• ALLENDE MC, LEE JW, FRANCIS P et al.: Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. (1994) 38(3):518–522.
   Google Scholar
• •Study of the activity of ABCD in treatment of experimental aspergillosis.
   Google Scholar
• HOSTETLER JS, CLEMONS KV, HANSON LH, STEVENS DA: Efficacy and safety of amphotericin B colloidal disper-sion compared with those of amphotericin B deoxycholate suspension for treatment of dissemi-nated murine cryptococcosis. Antimicrob. Agents Chemother. (1992) 36(12):2656–2660.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. (1998) 42(4):899–902.
   PubMed Web of Science ®Google Scholar
• •Comparative study of the lipid formulations of amphoteri-cicn B for the treatment of experimental cryptococcosis.
   Google Scholar
• FIELDING RM, SMITH PC, WANG LH, PORTER J, GUO LS: Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. (1991) 35 (6):1208–1213.
   Google Scholar
• SANDERS SW, BUCHI KN, GODDARD MS, LANG JK, TOLMAN KG: Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. (1991) 35(6):1029–1034.
   PubMed Web of Science ®Google Scholar
• KAN VL, BENNETT JE, AMANTEA MA et al.: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. (1991) 164(2):418–421.
   PubMed Web of Science ®Google Scholar
• LEENDERS AC, DE MARIE S: The use of lipid formula-tions of amphotericin B for systemic fungal infections. Leukemia (1996) 10(101570–1575.
   Web of Science ®Google Scholar
• BOWDEN RA, CAYS M, GOOLEY T, MAMELOK RD, van Bunk JA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. (1996) 173(5):1208–1215.
   PubMed Web of Science ®Google Scholar
• ••ABCD clinical trial.
   Google Scholar
• NOSKIN GA, PIETRELLI L, COFFEY G, GURWITH M, LIANG LJ: Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin. Infect. Dis. (1998) 26(2):461–467.
   Google Scholar
• ••Analysis of results of candidaemia treatment with ABCD.
   Google Scholar
• ANAISSIE EJ, MATTIUZZI GN, MILLER CB et al.: Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob. Agents Chemother. (1998) 42(3):606–611.
   Google Scholar
• ••ABCD clinical trial.
   Google Scholar
• OPPENHEIM BA, HERBRECHT R, KUSNE S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. (1995) 21(5):1145–1153.
   Google Scholar
• ••ABCD clinical trial.
   Google Scholar
• WHITE MH, ANAISSIE EJ, KUSNE S et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. (1997) 24(4)635–642.
   Google Scholar
• ••Analysis of results of aspergillosis treatment with ABCDversus amphotericin B deoxycholate.
   Google Scholar
• FIELDING RM, SINGER AW, WANG LH, BABBAR S, GUOLS: Relationship of pharmacokinetics and drug distri-bution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. (1992) 36(2):299–307.
   PubMed Web of Science ®Google Scholar
• AMANTEA MA, BOWDEN RA, FORREST A, WORKING PK,NEWMAN MS, MAMELOK RD: Population pharmacoki-netics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob. Agents Chemother. (1995) 39(9)2042–2047.
   Google Scholar
• GURWITH M, MAMELOK R, PIETRELLI L, DU MOND C: Renal sparing by amphotericin B colloidal dispersion: Clinical experience in 572 patients. Chemotherapy (1999) 45 (Suppl. 1)39–47.
   Google Scholar
• ••Analysis of nephrotoxicity of ABCD.
   Google Scholar
• NOSKIN G, PIETRELLI L, GURWITH M, BOWDEN R: Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant. (1999) 23(7)697–703.
   Google Scholar
• ••Analysis of results of use of ABCD in bone marrowtransplant recipients.
   Google Scholar
• HERBRECHT R, LETSCHER V, ANDRES E, CAVALIER A: Safety and efficacy of amphotericin B colloidal disper-sion - an overview. Chemotherapy (1999) 45 (Suppl. 1)67–76.
   Google Scholar
• DUPONT B: Clinical efficacy of amphotericin Bcolloidal dispersion against infections caused by Candida spp. Chemotherapy (1999) 45 (Suppl. 1)27–33.
   Google Scholar
• MOSES AE, RAHAV G, BARENHOLZ Y et al.: Rhinocere-bral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin. Infect. Dis. (1998) 26(6):1430–1433.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Overview of amphotericin B colloidal dispersion (amphocil). J. Infect. (1994) 1:45–49.
   Google Scholar
• DIETZE R, MILAN EP, BERMAN JD et al.: Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis. (1993) 17(6):981–986.
   PubMed Web of Science ®Google Scholar
• BERMAN J, DIETZE R: Treatment of visceral leishmania-sis with amphotericin B colloidal dispersion. Chemotherapy (1999) 1:54–66.
   Google Scholar
• DIETZE R, FAGUNDES SM, BRITO EF et al.: Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Transactions R. Soc. Trop. Med. Hygiene (1995) 89(3):309–311.
   PubMed Web of Science ®Google Scholar
• JOHNSON JR, KANGAS PJ, WEST M: Serious adverse event after unrecognized substitution of one amphotericin B lipid preparation for another. Clin. Infect. Dis. (1998) 27(5):1342–1343.
   PubMed Web of Science ®Google Scholar
• DIETZE R, FOWLER VG, JR., STEINER TS, PECANHA PM, COREY GR: Failure of amphotericin B colloidal disper-sion in the treatment of paracoccidioidomycosis. Am. Trop. Med. Hygiene (1999) 60(5):837–839.
   Google Scholar
• ANAISSIE EJ, DAROUICHE RO, ABI-SAID D eta].: Manage-ment of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. (1996) 23 (5):964–972.
   Google Scholar